Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
Statistics in Medicine · 2025
DOI: 10.1002/sim.70275 ↗At a glance
Journal article in Statistics in Medicine, 2025. Written by Alessandra Serra and 4 co-authors. Institution: University of Cambridge, MRC Biostatistics Unit, Cambridge, UK. Major MEDLINE topics: Research Design, Biomarkers, Clinical Trials as Topic. Cited 9 times so far (Crossref); 17 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research, Medical Research Council.
Abstract (original language)
Identifying and quantifying predictive biomarkers is a critical issue of Precision Medicine approaches and patient‐centric clinical development strategies. Early phase adaptive designs can improve trial efficiency by allowing for adaptations during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. At an early stage, the goal is not to precisely define the target population, but to not miss an efficacy signal that might be limited to a biomarker subgroup. In this work, we propose a one‐arm two‐stage early phase biomarker‐guided design in the setting of an oncology trial where at the time of the interim analysis, several decisions can be made regarding stopping the entire trial early or continuing to recruit patients from the full or a selected patient population. Via simulations, we show that, although the sample size is limited, the proposed design leads to better decision‐making compared to a classical design that does not consider an enrichment expansion.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University of Cambridge, MRC Biostatistics Unit, Cambridge, UK.
- Department of Statistical Methodology, Saryga, France.
- Translational Statistics Department, Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.
ORCID profiles: Alessandra Serra
Funding
- National Institute for Health and Care Research
- Medical Research Council
Cite
APA
Serra, A., Saint-Hilary, G., Guilleminot, S., Geronimi, J., & Mozgunov, P. (2025). Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70275
Vancouver
Serra A, Saint-Hilary G, Guilleminot S, Geronimi J, Mozgunov P. Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70275
BibTeX
@article{Serra2025,
author = {Serra, Alessandra and Saint-Hilary, Gaëlle and Guilleminot, Sandrine and Geronimi, Julia and Mozgunov, Pavel},
title = {Adaptive Biomarker‐Based Design for Early Phase Clinical Trials},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70275}
}
EUVIMED